Articles

Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;Department of Hematology, First Affiliated Hospital, Harbin Medical University, Harbin, China
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Oncology Biomarkers, Genentech, South San Francisco, CA, USA
Department of Hematology, First Affiliated Hospital, Harbin Medical University, Harbin, China
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Oncology Biomarkers, Genentech, South San Francisco, CA, USA
College of Medicine, Sharjah Institute for Medical Research, University of Sharjah, Sharjah, UAE;Division of Hematology/Oncology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
AbbVie Inc., North Chicago, IL, USA
AbbVie Inc., North Chicago, IL, USA
AbbVie Inc., North Chicago, IL, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Division of Hematology/Oncology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA
AbbVie Inc., North Chicago, IL, USA
Department of Translational Oncology, Genentech, South San Francisco, CA, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Vol. 105 No. 3 (2020): March, 2020 https://doi.org/10.3324/haematol.2018.205534